Dr. Amro Elshoury Amro Elshoury, MD

Amro Elshoury

MD
Hematologic Oncology

Specializing In:

Polycythemia Vera (PV) Myelofibrosis (MF) Mastocytosis Eosinophilia Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS) Acute leukemia (AML and ALL) Essential thrombocythemia
About Amro Elshoury

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Leukemia Service
  • Department of Medicine

Background

Education and Training:

  • 2011 - M.Sc. - Masters of Science in Hematology
  • 2009 - MD - Ain Shams University School of Medicine (M.B.B.Ch) Cairo, Egypt

Residency:

  • 2013 - Internal Medicine Residency, Albany Medical Center, Albany, NY

Fellowship:

  • 2012 - Research fellowship at Keck School of Medicine, University of Southern California, Los Angeles, CA
  • 2019 - Hematology and Medical Oncology Fellowship, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Board Certification:

  • American Board Of Internal Medicine

Professional Memberships:

  • American Society of Hematology
  • American Society for Blood and Marrow Transplantation
  • American Society of Clinical Oncology
  • The Egyptian Medical Syndicate

Honors & Awards:

  • 2018 - University at Buffalo (UB) Gerald L. Logue Award for outstanding medical trainee in hematology and oncology at Roswell Park
  • 2017 - Thomas F. Frawley, MD, Residency Research Fellowship Award – UB annual award for the outstanding medical trainee’s research
  • 2019 - Ain Shams University Top Academic Honors
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Learn More
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Learn More

Clinical Trials

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Learn More
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Learn More

Publications

  1. Elshoury A, Przespolewski A, Baron J, Wang ES. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. Expert Rev Anticancer Ther. 2019 Mar;19(3):273-286.
  2. Elshoury Amro, Wallace PK, Borowitz MJ, Kader A, Choi C, Ho C, Balderman S, Ross M, Hahn T, O'Neill V, McCarthy PL, Chen GL. BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2018 ;53(5):651-653.
  3. Elshoury A, Baron J, Przespolewski A, Wang E. Optimizing FLT3 Inhibitor Monotherapy in Acute Myeloid Leukemia. The journal of targeted therapies in cancer. 2017 December.
  4. Przespolewski A, Szeles, Elshoury A, Wang E. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia. Targeted oncology. 2017 October 25.
  5. Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution. Biol Blood Marrow Transplant. 2017 Sep;23(9):1437-1446.

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment